FDA has served L’Oreal SA with the firm’s second warning letter in three years in what could be intended as a signal to the cosmetics industry regarding claims in an increasingly popular segment – products that address hyperpigmentation – as well as a more established benefit in the dermocosmetic arena, redness reduction.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?